The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.